MRVI Life Sciences · Biotech tools · Turnaround · mRNA · Thesis updated July 2, 2026

TriLink recovery is still on trial

Q1 2026 revenue rose 40.5%, but a $14.3 million COVID CleanCap order drove much of the jump.
The better news was that base TriLink revenue grew 15.4% year over year after a long slide.
Management said it does not expect more high-volume COVID CleanCap orders in 2026.
Cygnus is steadier, but its 1.4% Q1 growth is too small to carry the whole company alone.
The 2025 realignment plan is meant to cut more than $65.0 million of annualized expenses.

01 Running thesis

A fragile first rebound

Maravai finally showed a cleaner sign of life in Q1 2026. Total revenue rose 40.5% year over year to $65.8 million, helped by a $14.3 million high-volume CleanCap order tied to COVID vaccines. Management said that order should not repeat during the rest of 2026, so the headline growth needs a discount.

The real bull point is under the headline. Excluding COVID CleanCap revenue, base TriLink revenue grew 15.4% year over year. That matters because TriLink had been falling hard through 2025, and this is the first clear sign that customer demand may have found a floor.

The bear case is still serious. In 2025, TriLink revenue fell 39.0%, and the company recorded goodwill and intangible asset impairments of $68.7 million. Those write-downs mean management cut its own view of what parts of the business can earn in the future.

Finn's overall view stays cautious. The recovery could be real, and cost cuts are helping margins. But the company still needs to prove that non-COVID TriLink demand can grow after the Q1 spike fades.

May 2026▲Q1 2026 revenue rose 40.5%, helped by a $14.3 million CleanCap order that should not repeat in 2026. The more important change was 15.4% growth in base TriLink revenue, the first clear sign of stabilization.

Feb 2026▼The 2025 10-K showed total revenue fell 28%, with TriLink down 39.0% as high-volume COVID CleanCap revenue disappeared. The company also recorded $68.7 million of goodwill and intangible asset impairments and pushed a major cost-cut plan.

Nov 2025▼Q3 2025 revenue fell 39.7% year over year, and the core Nucleic Acid Production segment fell 52.9%. Management also warned that weaker cash flow forecasts could put more long-lived assets at risk.

Aug 2025▼Q2 2025 brought a $30.4 million Alphazyme goodwill impairment and a 31.7% total revenue decline. Management answered with a Corporate Realignment Plan that included a roughly 25% workforce reduction.

May 2025▼Q1 2025 revenue fell 27.0%, led by a 37.5% decline in Nucleic Acid Production. Maravai also wrote off the remaining $12.4 million of TriLink goodwill.

Mar 2025▼Full-year 2024 revenue fell 10.3%, and management recorded another impairment in the core Nucleic Acid Production business. The filing showed weaker demand was already in reported results, not only in forecasts.

Nov 2024▼Maravai recorded a $154.2 million goodwill impairment in Nucleic Acid Production after lowering its near-term revenue forecast. Both main segments were still showing modest year-over-year declines.

Aug 2024→The initial thesis framed Maravai as a life science tools supplier with long-term mRNA exposure but near-term pressure from weaker biotech R&D spending and China softness. Q2 2024 showed mixed segment trends.

02 Business model

Tools for drug makers

Maravai sells products used by drug, vaccine, diagnostic, and research customers. Its TriLink unit makes modified nucleic acids, including CleanCap analogs and GMP mRNA. These are building blocks and process inputs for mRNA and other advanced therapy work.

Cygnus sells products and services that help biologic drug makers test for impurities. These tests matter because unwanted process materials can affect drug safety and quality.

Sales are mostly handled directly in North America. In Europe and Asia Pacific, Maravai uses a mix of direct sales and third-party distributors.

The company is now run like a turnaround. Its 2025 Corporate Realignment Plan targets more than $65.0 million in annualized expense cuts through a 25% workforce reduction and facilities consolidation. That can protect profit, but it can also damage execution if key people leave or customers feel disruption.

03 Product portfolio

What Maravai sells

Growth engine

CleanCap analogs

CleanCap analogs are used in mRNA vaccine and therapy production. Q1 2026 included a $14.3 million high-volume order for commercial COVID vaccine programs, but management does not expect more such orders in 2026.

Growth engine

GMP mRNA and nucleic acids

TriLink makes highly modified nucleic acids and GMP mRNA for customers moving from research into higher-grade production. This is the core area investors need to see stabilize.

Option

Discovery consumables

These products support early research and development work. Demand is tied to biotech R&D budgets, which have been constrained.

Option

Enzymatic DNA synthesis technology

Maravai added this technology through the 2025 acquisition of Molecular Assemblies assets. It gives the company another possible platform, but it still needs proof of commercial traction.

Option

AI therapeutic design platform

The Officinae Bio acquisition added an AI-powered design platform. It is a future-facing bet, not the current profit base.

Steady

Cygnus impurity testing

Cygnus provides antibody-based products and services that detect impurities in biologic drug manufacturing. It grew 1.4% year over year in Q1 2026, making it steadier than TriLink but not fast enough to carry Maravai by itself.

04 Business segments

Q1 mix favors TriLink

TriLink72%growing fast

Cygnus28%modest

Segment mix is from the three months ended March 31, 2026. TriLink was about 72.1% of revenue, but that period included a $14.3 million CleanCap order that management says should not repeat in 2026.

05 Risk factors

What could still break

Q1 was the peak, not the base

High impact · High odds

The Q1 2026 beat included $14.3 million of high-volume CleanCap revenue for COVID vaccine programs. Management said it does not expect more high-volume COVID CleanCap orders for the rest of 2026. If Q2 drops hard, investors may treat Q1 as a temporary bump, not a recovery.

We watchQ2 and Q3 2026 revenue excluding high-volume COVID CleanCap orders.

Base TriLink growth stalls again

High impact · Medium odds

Base TriLink revenue grew 15.4% year over year in Q1 2026. That is the strongest point in the current thesis. If it came from pent-up demand or easy comparisons, the turnaround case weakens fast.

We watchNon-COVID TriLink year-over-year growth for each remaining 2026 quarter.

Cost cuts hurt the business

Medium impact · Medium odds

The realignment plan targets more than $65.0 million in annualized expense cuts and includes a 25% workforce reduction. Those cuts can lift margins, but they can also cause employee attrition, customer disruption, or slower product work.

We watchOperating expenses, gross margin, customer service comments, and any new restructuring charges.

More impairment signals

High impact · Medium odds

Maravai recorded $68.7 million of goodwill and intangible asset impairments in 2025, after more than $178 million of prior write-downs. These charges are non-cash, but they show the company lowered its own view of future cash flows. More charges would be a warning that management still sees weak earning power.

We watchNew goodwill or intangible asset impairment language in future 10-Q and 10-K filings.

Biotech funding stays tight

Medium impact · Medium odds

Maravai sells into drug discovery and development markets. If early-stage biotech customers keep cutting R&D budgets, demand for discovery products can stay weak. Cygnus helps, but its 1.4% Q1 growth is not enough to offset a fresh TriLink downturn.

We watchCustomer commentary on biotech R&D budgets and Maravai demand for discovery products.

06 Quick answers

In one breath

What does Maravai LifeSciences do?

Maravai sells life science tools used to develop drugs, vaccines, diagnostics, and biologics. Its biggest unit, TriLink, focuses on mRNA and nucleic acid products, while Cygnus focuses on biologics safety testing.

Why did MRVI revenue jump in Q1 2026?

Revenue rose 40.5% year over year in Q1 2026. A $14.3 million high-volume CleanCap order for COVID vaccine programs drove much of that increase, and management said it does not expect more such orders in 2026.

What is the main turnaround signal for MRVI?

The key signal is base TriLink revenue, excluding COVID CleanCap revenue. It grew 15.4% year over year in Q1 2026, which suggests the core business may be stabilizing.

What is the biggest risk for MRVI stock?

The biggest risk is that Q1 2026 was a temporary spike. If non-COVID TriLink growth fades and cost cuts are not enough to hold profitability, the recovery case gets much weaker.